Skip to main content
MedicHelpLine
Join Free
Verified Professional Network190+ CountriesHIPAA-Aware Platform
Back to Drug Index
General MedicationsOPHTHALMICGeneric

BRINZOLAMIDE; BRIMONIDINE TARTRATE

BRINZOLAMIDE;BRIMONIDINE TARTRATE

Standard Dose
0.2MG,10MG
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: None (Tentative Approval)
Summary

Approval overview BRINZOLAMIDE; BRIMONIDINE TARTRATE is listed in Drugs@FDA under application 212137 (ANDA).

Review priority: STANDARD Marketing status: None (Tentative Approval) Active ingredient BRINZOLAMIDE;BRIMONIDINE TARTRATE Form and strength SUSPENSION/DROPS;OPHTHALMIC - 0.2MG,10MG Sponsor PERRIGO PHARMA INTERNATIONAL DAC Submission history Latest submission status date: 2023-11-29 00:00:00.

Structured Monograph

Clinical summary

Approval overview BRINZOLAMIDE; BRIMONIDINE TARTRATE is listed in Drugs@FDA under application 212137 (ANDA). Review priority: STANDARD Marketing status: None (Tentative Approval) Active ingredient BRINZOLAMIDE;BRIMONIDINE TARTRATE Form and strength SUSPENSION/DROPS;OPHTHALMIC - 0.2MG,10MG Sponsor PERRIGO PHARMA INTERNATIONAL DAC Submission history Latest submission status date: 2023-11-29 00:00:00. Submission type: ORIG.

Monitoring

  • • Marketing status: None (Tentative Approval)
  • • Review priority: STANDARD

Interaction Notes

  • No interaction notes stored yet.
BRINZOLAMIDE; BRIMONIDINE TARTRATE (BRINZOLAMIDE;BRIMONIDINE TARTRATE) | Drug Monograph | MedicHelpline